Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
Last trade$14.25
Day change-$0.485 (-3.29%)
Day range$14.12 – $15.26
Volume1,058,804
Market cap$1.61B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.61B
Price / earnings
5.46×
Price / book
1.66×
Price / sales
2.29×
EV / sales
1.27×
EV / EBITDA
2.98×
Profitability
Earnings per share
$2.70
Return on assets
24.67%
Return on equity
30.45%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
8.44×
Quick ratio
8.44×
Cash ratio
5.51×
Cash flow
Price / cash flow
4.24×
Price / free cash flow
4.35×
Free cash flow
$369.81M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NRIX, quarterly periods
Line item
Q3 FY2026 Aug 31, 2026
Q2 FY2026 May 31, 2026
Q1 FY2026 Feb 28, 2026
Q4 FY2025 Nov 30, 2025
Q3 FY2025 Aug 31, 2025
Q2 FY2025 May 31, 2025
Q1 FY2025 Feb 28, 2025
Q4 FY2024 Nov 30, 2024
Revenue
$673.06M
$9.04M
$6.25M
$13.58M
$7.89M
$44.06M
$18.45M
$13.28M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$673.06M
$9.04M
$6.25M
$13.58M
$7.89M
$44.06M
$18.45M
$13.28M
Selling, general and administrative
$34.35M
$15.59M
$14.61M
$13.65M
$13.16M
$14.28M
$11.65M
$10.72M
Research and development
$79.26M
$87.65M
$84.14M
$83.02M
$86.12M
$78.1M
$69.66M
$67.22M
Total operating expenses
$113.61M
$103.25M
$98.75M
$96.67M
$99.28M
$92.38M
$81.32M
$77.94M
Operating income
$559.45M
-$94.2M
-$92.5M
-$83.1M
-$91.39M
-$48.32M
-$62.86M
-$64.66M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
$563.41M
-$89.81M
-$87.17M
-$78.22M
-$86.42M
-$42.7M
-$56.35M
-$58.54M
Income taxes
$13.61M
-$271K
$0
$0
$0
$760K
$0
$8K
Net income
$549.81M
-$89.54M
-$87.17M
-$78.22M
-$86.42M
-$43.46M
-$56.35M
-$58.55M
Net income attributable to common shareholders
$549.81M
-$89.54M
-$87.17M
-$78.22M
-$86.42M
-$43.46M
-$56.35M
-$58.55M
EBITDA
$561.59M
-$91.95M
-$90.3M
-$80.98M
-$89.36M
-$46.08M
-$60.51M
-$62.11M
Basic earnings per share
$4.93
-$0.81
-$0.79
-$0.82
-$1.03
-$0.52
-$0.67
-$0.75
Diluted earnings per share
$4.73
-$0.81
-$0.79
-$0.82
-$1.03
-$0.52
-$0.67
-$0.75
Recent news
Company coverage with links to the original publishers.
Swiss pharma giant Roche Holding AG reported first-nine-month 2026 sales of CHF 46.5 billion, up 6% at constant exchange rates, driven by 7% growth in its Pharmaceuticals division. Five key drugs generated CHF 16.8 billion in sales, up 12% at CER, offsetting declines in legacy products due to loss of exclusivity. The company reaffirmed mid-single-digit sales growth guidance for 2026 and expects high-single-digit EPS growth. Roche's pipeline includes promising candidates in oncology, immunology, and obesity treatment, with enicepatide showing encouraging phase II results for type 2 diabetes and weight management.
Kymera Therapeutics is developing KT-621, an oral STAT6 degrader in phase IIb trials for atopic dermatitis and eosinophilic asthma. The company completed enrollment in the BROADEN2 study ahead of schedule with top-line data expected by end of 2026. Future growth depends on trial outcomes, regulatory approval, and successful commercialization. The company faces competition from Arvinas and Nurix in the protein degradation therapy space.
Nurix Therapeutics reported Q3 2026 earnings of $4.73 per share, significantly beating the consensus estimate of a loss of $0.56 per share, with a 944.64% earnings surprise. Revenues reached $673.06 million, surpassing estimates by 383.11%. However, the stock received a Zacks Rank #3 (Hold) rating, with mixed estimate revisions and the company's industry ranking in the bottom 33% of sectors.
Economic data shows mixed signals with softer-than-expected PCE inflation and stronger-than-expected Q2 GDP growth. Market attention is turning to Friday's employment report. Precigen shares surged 6.3% on growing investor confidence in sales of its FDA-approved drug Papzimeos for recurrent respiratory papillomatosis, with expected quarterly earnings up 181.8% year-over-year.
AnaptysBio (ANAB) reported a quarterly loss of $0.11 per share, beating consensus estimates of $0.46 loss, with a 76% earnings surprise. However, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends. The Medical - Biomedical and Genetics industry ranks in the bottom 32% of sectors. Nurix Therapeutics (NRIX) is expected to report results with a projected loss of $0.56 per share but with significant revenue growth of 1665.8% year-over-year.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.